Clinical Trials Logo

Clinical Trial Summary

A core symptom of body dysmorphic disorder (BDD) is perceptual distortions for appearance, which contributes to poor insight and delusionality, limits engagement in treatment, and puts individuals at risk for relapse. Results from this study will provide a comprehensive mechanistic model of brain, behavioral, and emotional contributors to abnormal perceptual processing, as well as how malleable it is with visual modulation techniques. This will lay the groundwork for next-step translational perceptual retraining approaches.


Clinical Trial Description

Individuals with body dysmorphic disorder (BDD) misperceive specific aspects of one's own appearance to be conspicuously flawed or defective, despite these being unnoticeable or appearing minuscule to others. With convictions of disfigurement and ugliness, individuals with BDD typically have poor insight or delusional beliefs, obsessive thoughts and compulsive behaviors, anxiety, and depression. These result in significant difficulties in functioning, depression, suicide attempts (25%), and psychiatric hospitalization (50%). Despite this, relatively few studies of the neurobiology, and few treatment studies, have been conducted. This underscores a critical need for research to identify novel targets for intervention based on a comprehensive understanding of the pathophysiological mechanisms. Neuropsychological, behavioral, and neurobiological research by investigators have uncovered mechanisms that may contribute to perceptual distortions, including prominent abnormalities in visual processing systems. These have contributed to a model of diminished global/holistic processing and enhanced local/detailed processing, attributed to "bottom-up" and "top-down" disturbances in perception. Using psychophysical experiments and novel visual modulation techniques, investigators have probed the brain's visual systems responsible for global and local processing and found early evidence that they may be modifiable in BDD. These techniques include a "top-down" attentional modulation and a "bottom-up" perceptual modulation strategy. Abnormal eye gaze and emotional arousal when viewing faces may further contribute to abnormal perception. Whether these brain and behavior abnormalities are directly linked to abnormal perception remains to be understood. Accordingly, this study will determine a) if abnormalities in neural activation and connectivity in BDD when viewing one's own appearance are directly associated with abnormalities in perceptual functioning; and b) if changes in neural activation and connectivity from these visual modulation strategies are linked to changes in perceptual functioning, thus representing potential biomarkers. Investigators will also determine how attentional systems, eye gaze behaviors and emotional arousal interact with brain functioning in visual systems, and with global and local perceptual functioning. Investigators will enroll participants with BDD, with subclinical BDD, and healthy controls who will undergo functional magnetic resonance imaging while viewing photographs of own, and others' faces. Investigators will obtain measures of global and local visual processing, emotional arousal while participants view own face, and eye gaze behaviors using eye tracking. To understand the malleability of global/local perception, and the neural mechanisms of these changes, investigators will determine whether repeated visual modulation using top-down and bottom-up strategies results in alterations of perceptual functioning and brain activity/connectivity, and relationships between them. Results will provide a comprehensive mechanistic model of abnormal visual information processing underlying the core symptom domain of misperceptions of appearance. This will lay the groundwork for next-step translational approaches. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04373629
Study type Interventional
Source Centre for Addiction and Mental Health
Contact Alexis Strazds
Phone (416) 535-8501
Email bdd.research@camh.ca
Status Recruiting
Phase N/A
Start date December 1, 2020
Completion date December 1, 2025

See also
  Status Clinical Trial Phase
Completed NCT02635152 - Interpretation Bias Modification for Body Dysmorphic Disorder N/A
Completed NCT03673046 - Waitlist-Control Trial of Smartphone Cognitive Behavioral Therapy (CBT) for Body Dysmorphic Disorder (BDD) N/A
Recruiting NCT05402475 - Online Cognitive Behavioural Therapy Intervention for Body Dysmorphic Disorder N/A
Withdrawn NCT02843451 - Milk Thistle in Body Dysmorphic Disorder Phase 2
Completed NCT02010619 - Internet Delivered CBT for Body Dysmorphic Disorder N/A
Completed NCT00842309 - D-Cycloserine Augmentation of Behavior Therapy for Individuals With Body Dysmorphic Disorder Early Phase 1
Completed NCT00245635 - Fluoxetine in Pediatric Body Dysmorphic Disorder Phase 4
Completed NCT02808702 - Brain Correlates of Self-Focused Processing N/A
Completed NCT01002326 - Cognitive-Behavioral Therapy for Pediatric Body Dysmorphic Disorder N/A
Active, not recruiting NCT01075672 - Outcomes of Cognitive Behavioral Therapy (CBT) Interventions Provided by Unlicensed Professionals N/A
Completed NCT02671266 - Oxytocin Administration in BDD and OCD Phase 2
Completed NCT01038128 - An Open Label Trial of Memantine in the Treatment of Bulimia Nervosa and Body Dysmorphic Disorder N/A
Completed NCT01398865 - Escitalopram Neuroimaging Supplement N/A
Completed NCT00265109 - Effectiveness of Levetiracetam in the Treatment of Body Dysmorphic Disorder Phase 4
Completed NCT01453439 - Cognitive-Behavioral Therapy and Supportive Psychotherapy for Body Dysmorphic Disorder N/A
Completed NCT00871143 - Cognitive Behaviour Therapy (CBT) for Body Dysmorphic Disorder (BDD) N/A
Completed NCT00106223 - Treatment Study Investigating New Cognitive Behavioral Therapy Treatment Manual for Body Dysmorphic Disorder N/A
Active, not recruiting NCT00211809 - CBT as an Adjunct to SRIs in the Treatment of BDD Phase 4